Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects-Reference-Cited by-同舟云学术

Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects

Published:2016-11 Issue:11 Volume:38 Page:2447-2458
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Dymond Angela W.,Howes Colin,Pattison Christine,So Karen,Mariani Gabriella,Savage Mark,Mair Stuart,Ford Gill,Martin Paul

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference13 articles.

1. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor;Yeh;Clin Cancer Res,2007

2. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer;Banerji;Clin Cancer Res,2010

3. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice;Denton;Cancer Chemother Pharmacol,2011

4. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer;Ho;N Engl J Med,2013

5. Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs);Widemann;J Clin Oncol,2014

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on tissue distribution, metabolite profiling, and excretion of [14C]-labeled flonoltinib maleate in rats;Journal of Pharmaceutical and Biomedical Analysis;2024-04

2. MEK Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

3. Targeted therapy;Medicines for Cancer;2023

4. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

5. Effect of food on capsule and granule formulations of selumetinib;Clinical and Translational Science;2022-02-15